Compare Lumen Technologies Inc (LUMN) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lumen Technologies Inc vs Zimmer Biomet Holdings Inc — how do they compare? Lumen Technologies Inc trades at $6.44 (market cap $6.47B), while Zimmer Biomet Holdings Inc trades at $90.03 (market cap $17.36B). The key difference: Zimmer Biomet Holdings Inc is far larger — about 2.7× Lumen Technologies Inc's market cap, and Zimmer Biomet Holdings Inc pays a 1.07% dividend while Lumen Technologies Inc pays none. Which is the better fit depends on your goals.
| LUMN | ZBH | |
|---|---|---|
Market Cap | $6.47B | $17.36B |
Sector | Media | Health |
52-Week High | $11.83 | $107.71 |
52-Week Low | $3.70 | $79.58 |
Enterprise Value | $18.10B | $24.40B |
Dividend Yield | — | 1.07% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
LUMN trades at $6.275, down 0.08% on the day, with a bearish technical signal but oversold RSI readings. The company reported a net loss of $1.74B in 2025 despite beating EPS estimates in two of the last three quarters. Recent news highlights strategic acquisitions like Alkira to bolster its AI networking capabilities, while the balance sheet shows high debt levels of $17.49B long-term.
The outlook remains challenging due to persistent losses and heavy debt, though cost-cutting initiatives and a $13B contract backlog offer potential upside. Analyst consensus is cautious with a $8.25 price target, but the stock's deep value (P/S 0.52) may attract contrarians if EBITDA improves. Key risks include execution on turnaround plans and interest expense pressure.
Zimmer Biomet (ZBH) trades at $89.74, down 1.51% on the day, with a bullish technical signal from moving averages and a consensus price target of $97.67. The company reported revenue of $8.23B in 2025, with net income of $705.10M and a net margin of 8.56%. Recent developments include expansion in Asia Pacific and a planned $1 billion share repurchase program, while Q2 2026 earnings are anticipated on August 5, 2026.
ZBH presents a mixed outlook with strong profitability margins and recent earnings beats offset by declining net income margins and rising debt levels. The stock offers potential upside to analyst targets but faces execution risks in competitive medical markets and macroeconomic pressures on healthcare spending.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Lumen Technologies Inc
With 450,000 route miles of fiber, including over 35,000 route miles of subsea fiber connecting Europe, Asia, and Latin America, Lumen Technologies is one of the United States' largest telecommunications carriers serving global enterprises. Its merger with Level 3 further shifted the company's operations toward businesses (over 70% of revenue) and away from its legacy consumer business. Lumen offers businesses a full menu of communications services, providing colocation and data center services, data transportation, and end-user phone and internet service. On the consumer side, Lumen provides broadband and phone service across 37 states, where it has 4.5 million broadband customers.
Read more on LUMN →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
